DNLI — Denali Therapeutics Balance Sheet

0.000.00%

Last trade - 00:00

HealthcareAdventurousMid CapNeutral

Annual balance sheet for Denali Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	—	—	—	—	—
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Cash and Equivalents
Short Term Investments
Cash and Short Term Investments	1,470	865	1,336	1,035	832
Net Total Receivables	5.67	1.23	0	—	—
Prepaid Expenses
Total Current Assets	1,496	897	1,372	1,064	864
Gross Property, Plant And Equipment
Accumulated Depreciation
Net Property, Plant And Equipment	73.5	69.6	74.5	71.6	126
Long Term Investments
Other Long Term Assets
Total Assets	1,604	1,404	1,460	1,154	1,374
Accounts Payable
Accrued Expenses
Notes Payable / Short Term Debt
Current Portion of Long Term Debt / Capital Leases
Total Other Current Liabilities
Total Current Liabilities	71.7	378	364	78	102
Capital Lease Obligations
Total Long Term Debt
Total Debt
Total Other Liabilities
Total Liabilities	454	442	418	123	144
Redeemable Preferred Stock
Common Stock
Additional Paid In Capital
Retained Earnings (Accumulated Deficit)
Other Equity
Total Equity	1,151	962	1,042	1,031	1,230
Total Liabilities & Shareholders' Equity	1,604	1,404	1,460	1,154	1,374
Total Common Shares Outstanding